查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840717

CBD 消费者健康市场（按产品类型和应用）—2025-2032 年全球预测

CBD Consumer Health Market by Product Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，CBD 消费者健康市场将成长至 415.6 亿美元，复合年增长率为 16.24%。

主要市场统计数据
基准年2024年 124.6亿美元
预计2025年 144.9亿美元
预测年份：2032年 415.6亿美元
复合年增长率（%） 16.24%

简要介绍当前消费者 CBD 健康格局、其加速发展以及对策略决策者的影响

随着社会对植物来源疗法态度的转变以及人们对传统药物替代品日益增长的需求，CBD健康类别已从最初的小众好奇发展成为注重健康的消费者群体的主流关注对象。过去几年，产品创新和零售扩张拓展了该类别的覆盖范围，包括药房柜檯、专业健康零售商以及以数位为先的直销管道。同时，科学探索和临床研究兴趣正在增强目标适应症的可信度，并推动更成熟的购买体验，将临床功效与生活方式定位相结合。

同时，政策和法律规范持续影响标籤、分销和行销的可接受性，影响产品设计和企业合规模式。因此，商业领袖正在快速进行商业性试验，并采取风险知情的声明、测试和供应链透明度方法。因此，能够展示严格品管、可靠证据和清晰讯息的公司将赢得消费者和通路合作伙伴的信任。

本执行摘要的其余部分将揭示不断变化的形势，评估近期关税行动的累积效应，提供细緻的细分见解，揭示区域模式和竞争行为，并为寻求将见解转化为行动的领导者提供实用建议。

快速的产品创新、监管调整和消费者成熟度如何重塑竞争动态和长期价值创造

这些措施正在加速产品创新，拓展CBD的交付和体验方式；监管调整限制并明确了允许的活动；临床和品质证据标准也不断提高，将普通产品与值得信赖的品牌区分开来。随着监管透明度的提高，大型零售商和机构投资者对上市产品更有信心，从而鼓励更多资本追求规模化，并进行更严格的研发投资以检验其功效。因此，该类别正从早期的实验阶段转向以卓越营运和监管素养驱动差异化的阶段。

同时，消费者也变得越来越精明。早期消费者更重视产品新颖性，而主流消费者在购买时则更重视功效、采购透明度和第三方侦测资讯。这种转变促使品牌在临床合作、真实世界证据收集和供应链可追溯性方面进行投资。零售商正透过提高验收标准和要求更严格的认证来应对这项挑战，奖励在品质保证和文件记录方面表现优异的公司，同时提高低品质製造商的进入门槛。

最后，分销模式也在不断发展。虽然数位通路仍然是关键的成长载体，但将精准电商与店内教育和样品相结合的全通路策略正日益受到青睐。总而言之，这些转型有利于那些能够将产品创新与合规框架、证据产生和全通路上市策略同步的组织。

近期关税对采购、製造业经济和策略供应链调整的整体影响（截至 2025 年）

近期的关税措施为该类别的供应链带来了新的复杂性，促使企业重新评估筹资策略和服务成本计算。进口关税及相关贸易措施提升了近岸外包和国内加工投资的重要性，因为企业试图保护其毛利率免受不可预测的跨境成本衝击的影响。为此，采购团队正在多元化其供应商组合，并提高库存透明度，以降低关税突然上调的风险。因此，随着企业在灵活性和可预测性之间做出权衡，长期合约和策略供应商伙伴关係已变得司空见惯。

这些关税主导的压力也加速了人们对垂直整合的兴趣，一些製造商寻求拥有提取和配方资产，以确保投入材料的质量，同时避免外部价格波动。同时，依赖进口最终产品的品牌正在重新调整其通路策略，转向更高价值的产品，并强调可追溯性和认证，以证明其高端定位的合理性。同时，面临净利率缩水的小品牌越来越多地与联合製造商合作或签订许可协议，以维持市场地位，而无需完全承担回流带来的资本负担。

总体而言，关税正在推动生态系统向更强的供应链弹性和战略本地化迈进，同时也促进了采购、合约结构和製造伙伴关係的创新，这将塑造超越当前政策週期的竞争地位。

细分领域的洞察揭示了产品创新、临床重点和通路策略在消费者 CBD 健康领域创造差异化价值的领域

将产品类型细分可以揭示消费者的需求和创新途径。胶囊和软胶囊吸引了那些寻求离散、定量剂量并与日常补充剂兼容的消费者，而油和酊剂则继续吸引那些优先考虑剂量控制和配方透明度的用户。烘焙点心和糖果甜点、饮料和软糖等偏好透过可用性和风味扩大了其吸引力，但也需要严格的标籤和剂量一致性以维护消费者的信任。外用药，包括润唇膏和软膏、乳霜和乳液以及贴片等子类别，越来越多地定位于疼痛管理和个人护理领域，其中配方稳定性和递送技术至关重要。电子烟产品分为烟弹和电子烟笔，仍然是一个利基管道，由于吸入问题，正引起越来越多的监管关注。

基于应用的细分进一步明确了临床证据和定製配方如何解锁高端定位。从一般焦虑管理到专注于创伤后压力症候群 (PTSD) 的配方，焦虑和压力应用需要谨慎的声明语言，并且通常受益于支持疗效的临床和现实世界证据。癫痫和多发性硬化症等神经系统疾病有临床先例支持，因此需要严格的采购和监管协调。疼痛管理涵盖关节炎、肌肉疼痛和神经病变疼痛，显示局部创新、标靶给药以及局部是关键的差异化因素。个人护理和护肤，包括护髮和护肤，为主流美容管道架起了桥樑，但需要明确的安全性和皮肤病学测试。睡眠障碍应用涵盖与失眠和睡眠呼吸中止相关的管理策略，重点突出优先考虑缓释性和与现有睡眠药物相互作用的配方和给药方案。

综合起来，这些细分模式表明，产品开发和证据生成策略应根据每个子细分市场的特定监管敏感性和临床期望进行定制，而商业策略应使渠道选择与用户行为和治疗意图保持一致。

区域模式和跨境动态影响监管风险、通路成熟度和全球公司的本地适应策略

美洲市场结构复杂多元，但制度化程度日益提高。联邦层级的监管模糊性与州和地方的健全框架并存。全国性品牌可以利用强大的零售网路和消费者熟悉度，但必须应对各州层级的复杂要求和不断变化的标籤规范。在这种环境下，与全国性零售商合作、投资合规团队以及根据具体州制定市场推广策略是常见的策略应对措施。

在欧洲、中东和非洲，儘管各国对安全标准和新型食品途径的解读仍有差异，但法律规范正逐渐协调。欧洲多个市场消费者意识的提升，推动了对经临床验证的产品和医药级生产方法的需求。同时，不断变化的进口和认证要求要求供应商必须掌握严谨的监管资讯并制定本地打入市场策略，尤其对于那些既想满足西欧挑剔的买家，又想满足新兴市场消费者对价值提案的供应商而言。

亚太地区市场成熟度参差不齐，既有严格监管、限制某些大麻素产品的市场，也有较为宽鬆、正在探索医疗和健康应用的司法管辖区。在成熟的城市中心，优质化和科学检验正成为赢得消费者信任的关键；而在其他市场，价格实惠以及与现有快速消费品管道的分销合作正在推动渗透。在全部区域，人们对植物疗法的文化态度以及医疗保健体系的结构将决定CBD产品是更倾向于与主流健康和医药管道，还是利基专业零售商接轨。

在每个地区，全球参与者必须将集中的品质和证据标准与分散的监管和商业性执行相结合，以抓住跨境商机，同时降低法律和声誉风险。

塑造消费者 CBD 健康生态系统中主要企业和新兴企业的竞争行为和企业策略

主要企业正透过证据产生、供应链透明度和通路多元化等措施实现差异化。其策略重点包括：投资第三方检测和追溯系统以检验产品功效；发展临床伙伴关係关係以产生可靠的疗效数据；以及拓展药房和临床医生青睐的管道，以满足更高的品质保证标准。同时，敏捷挑战者则致力于在细分领域占据领先地位，他们专注于特定用途和交付系统，利用直销市场建立有意义的品牌忠诚度，并利用敏捷的产品开发週期快速回应消费者回馈。

合併、策略联盟和许可安排是加速能力建构且不过度扩张资产负债表的常见机制。同时，忽略任何一个面向——品管、临床检验或通路准入——都会增加商业性风险。此外，投资者的注意力正转向那些能够展现重复购买行为、分销黏性以及可靠的规避监管审查计划的企业，从而导致对单位经济效益和客户生命週期价值的严格控制。

整体而言，竞争优势越来越取决于科学、合规和商业化的综合能力，而不是纯粹的分销扩张或短期促销活动。

高阶主管和投资者可以采取切实可行的优先行动，以增强韧性、抓住成长机会、管理监管和贸易动态

首先，我们将优先投资检验的品质系统和透明的供应链，以建立监管机构和消费者的信任。这包括标准化的第三方检测、批次可追溯性以及采购和生产实践的公开揭露。从中期来看，这些投资将减少与大型零售客户的摩擦，并支持我们的高端定价策略。其次，我们将根据差异化证据策略调整产品系列。我们将把临床和现实世界证据资源分配给最有可能值得检验的用途，例如疼痛管理和某些神经系统疾病，同时利用消费者研究来优化配方，以适应更注重生活方式的细分市场，例如个人护理和睡眠支持。

第三，根据关税和贸易波动重新评估製造地，考虑近岸外包、长期供应协议或外包製造外包方案，以维持利润率和服务水准。第四，多元化您的通路策略，在直接面向消费者的分析优势与药局和临床医师通路的可靠性之间取得平衡。最后，将情境规划纳入您的策略评估中，以便您可以根据您的商业计划和投资蓝图，对监管变化、关税变化和新兴临床洞察进行压力测试。结合这些行动，可以帮助组织将洞察转化为明确的市场定位和营运韧性。

产生洞察所采用的实证方法，包括资料来源、三角测量策略以及用于确保稳健性和有效性的检验方法

调查方法结合了主要和次要研究证据流，从而建构了对该品类的全面、立体的视角。主要研究包括对供应链领导者、零售和药房管道的高级品类采购员、产品开发主管以及临床顾问的结构化访谈，以了解决策驱动因素和营运限制。此外，也进行了消费行为研究，定性深入地探讨了目标族群的购买动机、产品认知和未满足的需求。次要研究则包括对监管出版物、公开临床文献、专利态势和零售品类分析的系统性回顾，以揭示市场动态和监管发展。

将采购声明与可观察到的贸易和供应商模式进行比较，根据同行评审文献评估临床声音，并透过神秘购物和电子商务产品组合审核检验零售定位。在公共资料匮乏或监管仍存在不确定性的情况下，明确承认其局限性，并进行敏感性检查，以确定哪些结论最容易受到政策或贸易条件变化的影响。这种混合方法提供了切实可行的见解，同时也突显了可以透过收集更多原始资料进一步降低不确定性的领域。

简要概括关键策略要点及其对整个价值链的经营团队行动和相关人员协调的影响

整体而言，消费者 CBD 健康类别正朝着更制度化、对证据的期望更高以及商业模式更加复杂的方向发展。监管动态和关税压力正在重塑供应链，并推动对近岸外包和垂直整合的投资。同时，细分洞察揭示了清晰的差异化途径。有些产品类型和治疗用途重视临床检验和配方严谨性，而有些则受益于品牌建立和感官创新。从区域来看，持续成长需要将全球品质标准与当地监管和文化差异结合。

对于领导者而言，成功显然需要一系列综合能力，包括合规性、临床证据、供应链韧性和通路策略。采取积极主动措施（例如强化品质系统、将证据生成用于高价值用途以及根据贸易现实调整製造布局）的公司将占据有利地位，能够将监管和市场波动转化为竞争优势。下一步，企业应将这些洞察转化为具体的投资和产业计画，并优先考虑短期韧性和长期品牌完整性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 快速引入奈米乳液 CBD 配方，以提高生物有效性和功效
  • 根据个人健康指标和目标量身定制的个人化 CBD 剂量应用程式的激增
  • 将 CBD 健康产品整合到远端医疗平台，为远距患者照护
  • 推出一款含有适应原的 CBD机能饮料，可全面缓解压力
  • CBD 对透明、第三方测试和区块链可追溯性的需求日益增长
  • CBD补充剂微剂量通讯协定的兴起以及焦虑和睡眠支持
  • CBD品牌转型为永续包装和碳中和供应链

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. CBD 消费者健康市场（依产品类型）

  • 胶囊和软胶囊
  • 食用
    • 烘焙点心和糖果甜点
    • 喝
    • 软糖
  • 油和酊剂
  • 外用药物
    • 香膏和药膏
    • 乳霜和乳液
    • 修补
  • 电子烟产品
    • 墨水匣
    • 电子烟

9. CBD 消费者健康市场（按应用）

  • 焦虑和压力
    • 整体焦虑
    • PTSD
  • 神经系统疾病
    • 癫痫
    • 多发性硬化症
  • 疼痛管理
    • 关节炎
    • 肌肉疼痛
    • 神经病变疼痛
  • 个人护理和化妆品
    • 护髮
    • 护肤
  • 睡眠障碍
    • 失眠
    • 睡眠呼吸中止症

10. CBD消费者健康市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 11 章：CBD 消费者健康市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

12. CBD消费者健康市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十三章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Charlotte's Web Holdings, Inc.
    • Social CBD, Inc.
    • Medterra CBD LLC
    • Green Roads Health, LLC
    • Lazarus Naturals, LLC
    • cbdMD, Inc.
    • CV Sciences, Inc.
    • CBDfx LLC
    • PlusCBD Oil, Inc.
    • Endoca Holland BV
Product Code: MRR-A339DAEFA242

The CBD Consumer Health Market is projected to grow by USD 41.56 billion at a CAGR of 16.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.46 billion
Estimated Year [2025] USD 14.49 billion
Forecast Year [2032] USD 41.56 billion
CAGR (%) 16.24%

A concise orientation to the current consumer CBD health landscape, its accelerating evolution, and implications for strategic decision-makers

The consumer CBD health category has matured from niche curiosity to a mainstream consideration among health-conscious consumers, catalyzed by shifting societal attitudes toward plant-based therapeutics and a growing appetite for alternatives to traditional pharmaceuticals. Over the past several years, product innovation and retail expansion have broadened the category's footprint across pharmacy counters, specialty wellness retailers, and digital-first direct-to-consumer channels. At the same time, scientific inquiry and clinical interest have elevated credibility for targeted indications, prompting more sophisticated buyer journeys that combine clinical claims with lifestyle positioning.

Meanwhile, policy and regulatory frameworks continue to shape what is permissible in labeling, distribution, and marketing, which in turn influence product design and corporate compliance models. As a result, commercial leaders are balancing rapid commercial experimentation with risk-aware approaches to claims, testing, and supply chain transparency. Consequently, companies that can demonstrate rigorous quality controls, credible evidence, and clear messaging are better positioned to win the trust of both consumers and channel partners.

The remainder of this executive summary will unpack the transformative shifts in the landscape, assess the cumulative effects of recent tariff actions, surface nuanced segmentation insights, highlight regional patterns and competitive behaviors, and conclude with pragmatic recommendations for leaders seeking to convert insight into action.

How rapid product innovation, regulatory recalibration, and consumer sophistication are reshaping competitive dynamics and long-term value creation

The landscape has been reshaped by three interlocking forces: accelerated product innovation that expands how CBD is delivered and experienced, regulatory recalibration that constrains and clarifies permissible activity, and a rising standard of clinical and quality evidence that separates commodity offerings from trusted brands. These forces are reinforcing each other; as regulations clarify, larger retailers and institutional buyers gain confidence to list products, prompting more capital to pursue scale and more rigorous R&D investments to validate claims. Consequently, the category is moving from early-stage experimentation to a phase where operational excellence and regulatory literacy drive differentiation.

Concurrently, consumer sophistication is rising. Early adopters prioritized novelty, but mainstream buyers evaluate efficacy, sourcing transparency, and third-party testing information during purchase. This shift incentivizes brands to invest in clinical collaborations, real-world evidence collection, and supply chain traceability. Retailers are responding by tightening onboarding criteria and demanding robust certifications, which increases barriers to entry for low-quality manufacturers while rewarding firms that excel in quality assurance and documentation.

Finally, distribution models are evolving. Digital channels continue to be an important growth vector, but omnichannel strategies that combine e-commerce precision with in-store education and sampling are gaining traction. In sum, these transformative shifts favor organizations that can synchronize product innovation with compliance frameworks, evidence generation, and an omnichannel go-to-market approach.

The aggregated influence of recent tariff measures on sourcing, manufacturing economics, and strategic supply chain adjustments through 2025

Recent tariff actions have introduced a new layer of complexity into the category's supply chains, prompting companies to reassess sourcing strategies and cost-to-serve calculations. Import duties and related trade measures have elevated the importance of nearshoring and domestic processing investments as firms seek to insulate gross margins from unpredictable cross-border cost shocks. In response, procurement teams are diversifying supplier portfolios and increasing inventory visibility to reduce exposure to sudden duty increases. Consequently, long-term contracting and strategic supplier partnerships have become more common as firms trade off flexibility for predictability.

These tariff-driven pressures have also accelerated interest in vertical integration, with some manufacturers exploring ownership stakes in extraction and formulation assets to secure input quality while buffering against external price volatility. Meanwhile, brands that rely on imported finished goods are recalibrating channel strategies, shifting to higher-value offerings and emphasizing traceability and certification as a way to justify premium positioning. At the same time, smaller brands facing tightened margins are increasingly forming alliances with co-manufacturers or pursuing licensing arrangements to maintain market presence without absorbing the full capital burden of reshoring.

In total, tariffs have nudged the ecosystem toward greater supply chain resilience and strategic localization, while simultaneously driving innovation in procurement, contract structuring, and manufacturing partnerships that will shape competitive positioning beyond the immediate policy cycle.

Segment-level insights that reveal where product innovation, clinical focus, and channel strategies are creating differentiated value across the consumer CBD health universe

Examining product-type segmentation reveals distinct consumer needs and innovation pathways. Capsules and softgels attract consumers seeking discrete, measured dosing and compatibility with daily supplement routines, while oils and tinctures continue to serve users focused on dose control and formulation transparency. Edibles, including baked goods and confectionery, beverages, and gummies, have expanded accessibility and flavor-driven appeal, but they also demand rigorous labeling and dosing consistency to preserve consumer trust. Topicals, with subcategories such as balms and salves, creams and lotions, and patches, are increasingly positioned within pain management and personal care contexts where formulation stability and delivery technology matter. Vape products, divided into cartridges and vape pens, remain a niche channel with heightened regulatory attention due to inhalation concerns, which has pushed some incumbents to deprioritize this route in favor of non-inhalation delivery systems.

Application-based segmentation further clarifies where clinical evidence and tailored formulations can unlock premium positioning. Anxiety and stress applications, from general anxiety management to PTSD-focused formulations, require careful claim language and often benefit from clinical or real-world evidence to support efficacy. Neurological disorder applications, such as epilepsy and multiple sclerosis, are anchored by clinical precedent and therefore demand rigorous sourcing and regulatory alignment. Pain management spans arthritis, muscle aches and pains, and neuropathic pain, signaling that topical innovation, targeted delivery, and cross-modal strategies combining oral and topical approaches are key differentiators. Personal care and cosmetics, including hair care and skincare, offer a bridge to mainstream beauty channels but require clear safety and dermatological testing. Sleep disorder applications, covering insomnia and sleep apnea-related management strategies, spotlight formulations and delivery profiles that prioritize sustained-release and interaction with existing sleep therapeutics.

Taken together, these segmentation patterns indicate that product development and evidence-generation strategies should be tailored to the specific regulatory sensitivities and clinical expectations of each subsegment, while commercial strategies must align channel choice with user behavior and therapeutic intent.

Regional patterns and cross-border dynamics that influence regulatory risk, channel maturity, and local adaptation strategies for global players

The Americas exhibit a heterogeneous but increasingly institutionalized market structure where regulatory ambiguity at the federal level coexists with robust state and provincial frameworks. This creates both opportunity and complexity: domestic brands can leverage strong retail networks and consumer familiarity, yet they must navigate a patchwork of state-level requirements and evolving labeling norms. In such an environment, partnerships with national retailers, investment in compliance teams, and state-specific go-to-market playbooks are common strategic responses.

In Europe, the Middle East & Africa, regulatory frameworks are progressively harmonizing around safety standards and novel-food pathways, though national interpretations still vary. Consumer awareness is rising across several European markets, driving demand for clinically supported products and pharmaceutical-grade manufacturing practices. At the same time, evolving import and certification requirements necessitate careful regulatory intelligence and local market entry strategies, particularly for suppliers aiming to serve both Western European discretionary buyers and emerging market consumers seeking value propositions.

Asia-Pacific reflects a spectrum of maturity levels, from highly regulated markets that restrict certain cannabinoid products to more permissive jurisdictions experimenting with medical and wellness applications. In mature urban centers, premiumization and scientific validation are becoming central to winning consumer trust, while in other markets, affordability and distribution partnerships with established FMCG channels drive penetration. Across the region, cultural attitudes toward botanical therapies and the structure of healthcare systems will dictate whether CBD products align more closely with mainstream wellness, pharmaceutical channels, or niche specialty retailers.

Across regions, global players must blend centralized quality and evidence standards with decentralized regulatory and commercial execution to capture cross-border opportunities while mitigating legal and reputational risk.

Competitive behavior and corporate strategies shaping the leading and emerging companies in the consumer CBD health ecosystem

Leading companies are differentiating through a blend of evidence generation, supply chain transparency, and channel diversification. Strategic priorities include investing in third-party testing and traceability systems to validate product claims, forging clinical partnerships to produce credible efficacy data, and expanding into pharmacy and clinician-recommended channels that reward higher levels of quality assurance. At the same time, nimble challengers are pursuing niche leadership by focusing on specific applications or delivery systems, leveraging direct-to-consumer marketing to build meaningful brand loyalty, and using agile product development cycles to respond rapidly to consumer feedback.

Mergers, strategic alliances, and licensing arrangements are common mechanisms for accelerating capability build-out without overextending balance sheets. Companies that combine manufacturing strength with strong marketing and regulatory affairs teams tend to scale more sustainably, while those that neglect any one dimension-be it quality control, clinical validation, or channel access-face elevated commercial risk. Moreover, investor interest has shifted toward businesses that can demonstrate repeat purchase behavior, distribution stickiness, and a credible plan for navigating regulatory scrutiny, which reinforces a discipline around unit economics and customer lifetime value.

Overall, competitive advantage is increasingly a function of integrated capability across science, compliance, and commercialization, rather than purely distributional breadth or short-term promotional activity.

Practical, prioritized actions that senior executives and investors can implement to strengthen resilience, capture growth, and manage regulatory and trade dynamics

First, prioritize investment in verifiable quality systems and transparent supply chain practices to establish trust with both regulators and consumers. This includes standardized third-party testing, batch traceability, and publicly accessible documentation of sourcing and manufacturing practices. In the medium term, such investments reduce friction with large retail customers and support premium pricing strategies. Second, align product portfolios with differentiated evidence strategies: allocate clinical and real-world evidence resources to the applications most likely to reward validation, such as pain management and certain neurological indications, while using consumer research to optimize formulations for more lifestyle-oriented segments like personal care and sleep support.

Third, re-evaluate manufacturing footprint in light of tariff and trade volatility by exploring nearshoring, long-term supply agreements, or contracted manufacturing options that preserve margin and service levels. Fourth, diversify channel strategies to balance direct-to-consumer analytics with the credibility benefits of pharmacy and clinician channels; tailored merchandising, training, and clinician education programs frequently unlock high-value partnerships. Finally, embed scenario planning into strategic reviews so that regulatory shifts, tariff changes, or new clinical findings can be stress-tested against commercial plans and investment roadmaps. Taken together, these actions will help organizations convert insight into defensible market positions and operational resilience.

Empirical approach deployed to generate insights, including data sources, triangulation strategies, and validation methods used to ensure robustness and relevance

The research methodology combined primary and secondary evidence streams to create a robust, triangulated view of the category. Primary research included structured interviews with supply chain leaders, senior category buyers across retail and pharmacy channels, product development executives, and clinical advisors to capture decision drivers and operational constraints. In parallel, consumer behavior studies provided qualitative depth on purchase motivations, product perceptions, and unmet needs among target cohorts. Secondary research comprised a systematic review of regulatory publications, public clinical literature, patent landscapes, and retail assortment analyses to contextualize market dynamics and regulatory trajectories.

To ensure validity, findings from different sources were cross-checked and reconciled: procurement claims were compared with observable trade and supplier patterns, clinical assertions were evaluated against peer-reviewed literature, and retail positioning was validated through mystery shopping and e-commerce assortment audits. Limitations were explicitly acknowledged where public data is sparse or regulatory opacity persists, and sensitivity checks were performed to identify which conclusions were most susceptible to changing policy or trade conditions. This mixed-methods approach delivers actionable insights while transparently flagging areas where additional primary data collection would further reduce uncertainty.

A concise synthesis of the key strategic takeaways and their implications for executive action and stakeholder alignment across the value chain

In synthesis, the consumer CBD health category is evolving toward greater institutionalization, higher evidence expectations, and more sophisticated commercial models. Regulatory dynamics and tariff pressures are restructuring supply chains and prompting investments in nearshoring and vertical integration. At the same time, segmentation insights reveal clear vectors for differentiation: certain product types and therapeutic applications reward clinical validation and formulation rigor, while others benefit from branding and sensory innovation. Regionally, companies must align global quality standards with local regulatory and cultural nuances to unlock durable growth.

For leaders, the implication is clear: success will require integrated capabilities across compliance, clinical evidence, supply chain resilience, and channel strategy. Those who act proactively-strengthening quality systems, targeting evidence generation to high-value applications, and adapting manufacturing footprint to trade realities-will be better positioned to convert regulatory and market disruptions into competitive advantage. As a next step, organizations should translate these insights into concrete investment and operating plans that prioritize both short-term resilience and long-term brand credibility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of nanoemulsion CBD formulations enhancing bioavailability and efficacy
  • 5.2. Surge in personalized CBD dosing apps tailored to individual health metrics and goals
  • 5.3. Integration of CBD wellness products into telehealth platforms for remote patient care
  • 5.4. Emergence of CBD functional beverages infused with adaptogens for holistic stress relief
  • 5.5. Growing demand for transparent third-party testing and blockchain traceability in CBD
  • 5.6. Rise of microdosing protocols for targeted anxiety and sleep support in CBD supplements
  • 5.7. Shift toward sustainable packaging and carbon-neutral supply chains in CBD brands

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CBD Consumer Health Market, by Product Type

  • 8.1. Capsules & Softgels
  • 8.2. Edibles
    • 8.2.1. Baked Goods & Confectionery
    • 8.2.2. Beverages
    • 8.2.3. Gummies
  • 8.3. Oils & Tinctures
  • 8.4. Topicals
    • 8.4.1. Balms & Salves
    • 8.4.2. Creams & Lotions
    • 8.4.3. Patches
  • 8.5. Vape Products
    • 8.5.1. Cartridges
    • 8.5.2. Vape Pens

9. CBD Consumer Health Market, by Application

  • 9.1. Anxiety & Stress
    • 9.1.1. General Anxiety
    • 9.1.2. PTSD
  • 9.2. Neurological Disorders
    • 9.2.1. Epilepsy
    • 9.2.2. Multiple Sclerosis
  • 9.3. Pain Management
    • 9.3.1. Arthritis
    • 9.3.2. Muscle Aches & Pains
    • 9.3.3. Neuropathic Pain
  • 9.4. Personal Care & Cosmetics
    • 9.4.1. Hair Care
    • 9.4.2. Skincare
  • 9.5. Sleep Disorders
    • 9.5.1. Insomnia
    • 9.5.2. Sleep Apnea

10. CBD Consumer Health Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. CBD Consumer Health Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. CBD Consumer Health Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Charlotte's Web Holdings, Inc.
    • 13.3.2. Social CBD, Inc.
    • 13.3.3. Medterra CBD LLC
    • 13.3.4. Green Roads Health, LLC
    • 13.3.5. Lazarus Naturals, LLC
    • 13.3.6. cbdMD, Inc.
    • 13.3.7. CV Sciences, Inc.
    • 13.3.8. CBDfx LLC
    • 13.3.9. PlusCBD Oil, Inc.
    • 13.3.10. Endoca Holland B.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. CBD CONSUMER HEALTH MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. CBD CONSUMER HEALTH MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CBD CONSUMER HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CAPSULES & SOFTGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BAKED GOODS & CONFECTIONERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GUMMIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY OILS & TINCTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY BALMS & SALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CREAMS & LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY GENERAL ANXIETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PTSD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY MUSCLE ACHES & PAINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY HAIR CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SKINCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP APNEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CBD CONSUMER HEALTH MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY PERSONAL CARE & COSMETICS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CBD CONSUMER HEALTH MARKET SIZE, BY SLEEP DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY EDIBLES, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY TOPICALS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY VAPE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST CBD CONSUMER HEALTH MARKET SIZE, BY ANXIETY & STRESS, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST CBD CONSUM